Dynamic changes in peripheral blood lymphocyte subsets predict the efficacy and prognosis of immune checkpoint inhibitors in metastatic osteosarcoma - Scorecard - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Alterations in Peripheral Blood Lymphocyte Subpopulations as Predictors of Immune Checkpoint Inhibitor Efficacy and Prognosis in Metastatic Osteosarcoma
Clinical Scorecard: Alterations in Peripheral Blood Lymphocyte Subpopulations as Predictors of Immune Checkpoint Inhibitor Efficacy and Prognosis in Metastatic Osteosarcoma
At a Glance
Category
Detail
Condition
Key Mechanisms
Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4 pathways, with emphasis on their variable efficacy in metastatic osteosarcoma.
Target Population
Care Setting
Key Highlights
Pre-ICIs CD8+HLA-DR+ and post-ICIs CD3−CD56+, CD3+CD4+, CD8+HLA-DR+ cells are protective for overall survival, with extrapulmonary metastasis identified as a significant risk factor.
Guideline-Based Recommendations
Diagnosis
Management
Consider immune monitoring through peripheral blood lymphocyte subsets for predicting ICI efficacy, with specific monitoring intervals suggested.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Heightened levels of CD3−CD56+ and CD8+HLA-DR+ cells post-ICIs are linked to better survival and response, suggesting a need for tailored treatment approaches.
Clinical Best Practices
Utilize flow cytometry to assess lymphocyte subsets in patients receiving ICIs, and incorporate dynamic immune monitoring into treatment protocols for personalized therapy, with examples provided.
